Compugen (CGEN) Shareholder's Equity Growth (5y) (2014 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Compugen | 234.03 Mn | 142.28 Mn | 352,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.02% |
| Sep 30, 2025 | -19.20% |
| Jun 30, 2025 | -17.24% |
| Mar 31, 2025 | -12.93% |
| Dec 31, 2024 | 7.46% |
| Sep 30, 2024 | 7.64% |
| Jun 30, 2024 | 12.91% |
| Mar 31, 2024 | 12.39% |
| Dec 31, 2023 | 11.97% |
| Sep 30, 2023 | 6.88% |
| Jun 30, 2023 | 8.86% |
| Mar 31, 2023 | 17.88% |
| Dec 31, 2022 | 21.53% |
| Sep 30, 2022 | 16.00% |
| Jun 30, 2022 | 13.86% |
| Mar 31, 2022 | 11.97% |
| Dec 31, 2021 | 10.93% |
| Sep 30, 2021 | 7.03% |
| Jun 30, 2021 | 6.04% |
| Mar 31, 2021 | 5.99% |
| Dec 31, 2020 | 5.91% |
| Sep 30, 2020 | 7.31% |
| Jun 30, 2020 | 6.29% |
| Mar 31, 2020 | 2.48% |
| Dec 31, 2019 | -18.43% |
| Sep 30, 2019 | -17.01% |
| Jun 30, 2019 | -20.18% |
| Mar 31, 2019 | -19.74% |
| Dec 31, 2018 | 3.15% |
| Sep 30, 2018 | 7.14% |
| Jun 30, 2018 | 14.38% |
| Mar 31, 2018 | 6.92% |
| Dec 31, 2017 | 10.64% |
| Sep 30, 2017 | 15.25% |
| Jun 30, 2017 | 16.63% |
| Mar 31, 2017 | 21.28% |
| Dec 31, 2016 | 26.54% |
| Sep 30, 2016 | 25.94% |
| Jun 30, 2016 | 24.47% |
| Mar 31, 2016 | 25.22% |
| Dec 31, 2015 | 26.02% |
| Sep 30, 2015 | 27.19% |
| Jun 30, 2015 | 29.36% |
| Mar 31, 2015 | 28.67% |
| Dec 31, 2014 | 31.10% |
| Sep 30, 2014 | 62.47% |
| Jun 30, 2014 | 55.04% |
| Mar 31, 2014 | 62.19% |